Once-failed cancer drug from BioXcel ramps up immunotherapy in mouse models of pancreatic cancer – FierceBiotech

When BioXcel Therapeutics raised $60 million in an initial public offering a few years back, it said it would pour part of the proceeds into developing talabostat, a drug that failed a phase 3 trial in pancreatic cancer in 2007. Now, BioXcel, along with…

Click here to view the original article.